Skip to main content
SpringerLink
Log in

Using Pharmacoepidemiologic Studies to Inform Drug Policy and Spending: A Health Economics Perspective

  • Chapter
  • First Online:
Healthcare Policy, Innovation and Digitalization

Abstract

Healthcare resource allocation today is more difficult than ever. The asymmetry between available resources and health needs requires methodologically sound and transparent decision-making processes for resource allocation. Clinical effectiveness and cost-effectiveness of health technologies are major determinants of pricing and reimbursement decisions—however, the above must be demonstrated both in the controlled and in the real-world setting. Pharmacoepidemiology can play a major role in evidence-informed pharmaceutical policy decisions, determining what “actually works” in real-life conditions. We discuss the role of pharmacoepidemiology in the decision-making context of pharmaceutical policy and, in specific, its role in the resource allocation framework, focusing on its impact on Health Technology Assessment, the efficiency of spending, and handling of uncertainty in coverage decisions, the latter achieved through risk-sharing schemes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 7(10):153. https://doi.org/10.1186/1472-6963-10-153

    Article  Google Scholar 

  • Alarkawi D, Ali MS, Bliuc D et al (2018) The challenges and opportunities of pharmacoepidemiology in bone diseases. JBMR Plus 2(4):187–194

    Article  Google Scholar 

  • Allen N, Walker SR, Liberti L, Salek S (2017) Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Heal 20(3):320–328. https://doi.org/10.1016/j.jval.2016.10.014

    Article  Google Scholar 

  • Babar Z (2019) Encyclopedia of pharmacy practice and clinical pharmacy, 1st edn. Elsevier Academic Press

    Google Scholar 

  • Balçık YP, Şantaş G (2016) Pharmacoepidemiology. IOSR J Pharm 6:2250-3013

    Google Scholar 

  • Baltussen R, Niessen L (2006) Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc 21(4):14. https://doi.org/10.1186/1478-7547-4-14

    Article  Google Scholar 

  • Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA (2020) Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf 29(10):1201–1212. https://doi.org/10.1002/pds.4932

    Article  Google Scholar 

  • Bégaud B (2019) A history of pharmacoepidemiology. Therapie 74(2):175–179. https://doi.org/10.1016/j.therap.2018.10.003

    Article  Google Scholar 

  • Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel MC (2017) Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf 26(9):1033–1039. https://doi.org/10.1002/pds.4297

    Article  Google Scholar 

  • Bloom BR, Michaud, CM, La Montagne JR, Simonsen L (2006) Priorities for global research and development of interventions. In: Jamison DT, Breman JG, Measham AR et al (eds) Disease control priorities in developing countries, 2nd edn. World Bank, Washington, DC. ISBN 978-0-8213-6179-5. PMID 21250329. Retrieved 2016-06-30

    Google Scholar 

  • Bolislis WR, de Lucia ML, Dolz F, Mo R, Nagaoka M, Rodriguez H, Woon ML, Yu W, Kühler TC (2021) Regulatory agilities in the time of COVID-19: overview, trends, and opportunities. Clin Ther 43(1):124–139. https://doi.org/10.1016/j.clinthera.2020.11.015

    Article  Google Scholar 

  • Caparrotta TM, Dear JW, Colhoun HM, Webb DJ (2019) Pharmacoepidemiology: using randomised control trials and observational studies in clinical decision-making. Br J Clin Pharmacol 85(9):1907–1924. https://doi.org/10.1111/bcp.14024

    Article  Google Scholar 

  • Chen G, Qin Y, Fan QQ, Zhao B, Mei D, Li XM (2020) Renal adverse effects following the use of different immune checkpoint inhibitor regimens: a real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med 9(18):6576–6585. https://doi.org/10.1002/cam4.3198

    Article  Google Scholar 

  • Comer D, Couto J, Aguiar R, Wu P, Elliott D (2015) Using aggregated pharmacy claims to identify primary nonadherence. Am J Manag Care 21(12):e655–e660

    Google Scholar 

  • Espín J, Rovira J, Gracia L, Andalusian School of Public Health (2011) Experiences and impact of European risk–sharing schemes focusing on oncology medicines experiences and impact of European risk-sharing schemes focusing on oncology medicines, available from: http://ec.europa.eu/DocsRoom/documents/7608/attachments/1/translations/en/renditions/pdf

  • FDA (2018) Real-world evidence, available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed on May 3, 2021

  • Frois C, Grueger J (2017) Pricing of pharmaceuticals: current trends and outlook and the role of comparative effectiveness research. In: Birnbaum H, Greenberg P (eds) Decision making in a world of comparative effectiveness research. Adis, Singapore. https://doi.org/10.1007/978-981-10-3262-2_7

  • Garber AM, McClellan MB (2007) Satisfaction guaranteed—“payment by results” for biologic agents. N Engl J Med 357(16):1575–1577. https://doi.org/10.1056/NEJMp078204

    Article  Google Scholar 

  • Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M (2013) Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Heal 16(5):703–719. https://doi.org/10.1016/j.jval.2013.04.011

  • Gliklich RE, Dreyer NA, Leavy MB (eds) (2014) Registries for evaluating patient outcomes: a user's guide [Internet], 3rd edn. Agency for Healthcare Research and Quality (US), Rockville, MD. Report No.: 13(14)-EHC111

    Google Scholar 

  • Harwood M, Deighton A, Mickle A, et al (2019) The use of real-world data in health technology assessment of medications for rare diseases. Value Heal 22(Suppl 3):S863. Poster presentation at the ISPOR Europe

    Google Scholar 

  • Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12(2):159–166. https://doi.org/10.1586/erp.12.8

    Article  Google Scholar 

  • Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107(31–32):543–551. https://doi.org/10.3238/arztebl.2010.0543

    Article  Google Scholar 

  • Hughes D, Cowell W, Koncz T, et al (2007) International society for pharmacoeconomics and outcomes research economics of medication compliance working group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Heal 10(6):498–509

    Google Scholar 

  • Institute of Medicine (IOM) Initial national priorities for comparative effectiveness research. The National Academies Press, Washington, DC

    Google Scholar 

  • Izano MA, Lo JC, Adams AL, Ettinger B, Ott SM, Chandra M, Hui RL, Niu F, Li BH, Neugebauer RS (2020) Bisphosphonate treatment beyond 5 years and hip fracture risk in older Wwmen. JAMA Netw Open 3(12):e2025190. https://doi.org/10.1001/jamanetworkopen.2020.25190

    Article  Google Scholar 

  • Jao R, Jaksa A, Pontynen A, et al (2018) Health technology assessment (HTA) agencies consideration of real world evidence (RWE). Value Heal 21(21):S 7. https://doi.org/10.1016/j.jval.2018.04.032

  • Jonker CJ, van den Berg HM, Kwa MSG, Hoes AW, Mol PGM (2017) Registries supporting new drug applications. Pharmacoepidemiol Drug Saf 26(12):1451–1457. https://doi.org/10.1002/pds.4332

    Article  Google Scholar 

  • Kanavos P, Tzouma V, Fontrier AM, Souliotis K (2019) Implementing health technology assessment (HTA) in Greece. Myths, Reality Cautionary Tales, Archiv Hellen Med 36(4):444–451

    Google Scholar 

  • Larsson S, Lawyer P, Garellick G, Lindahl B, Lundström M (2012) Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care’s value. Health Aff (millwood) 31(1):220–227. https://doi.org/10.1377/hlthaff.2011.0762

    Article  Google Scholar 

  • Levine M, Lelorier J (2012) Pharmacoepidemiology and pharmaceutical reimbursement policy. In: Brian L, Strom MD, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology, 5th edn. Wiley

    Google Scholar 

  • Lou J, Kc S, Toh KY, Dabak S, Adler A, Ahn J, Bayani DBS, Chan K, Choiphel D, Chua B, Genuino AJ, Guerrero AM, Kearney B, Lin LW, Liu Y, Nakamura R, Pearce F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Teerawattananon Y, Tunis S, Wu HM, Zalcberg J, Zhao K, Isaranuwatchai W, Wee HL (2020) Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Int J Technol Assess Health Care 36(5):474–480. https://doi.org/10.1017/S0266462320000628

    Article  Google Scholar 

  • Makady A, van Veelen A, Jonsson P, Moseley O, D’Andon A, de Boer A, Hillege H, Klungel O, Goettsch W (2018) Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics 36(3):359–368. https://doi.org/10.1007/s40273-017-0596-z

    Article  Google Scholar 

  • Martin LA, Neumann CW, Mountford J et al (2009) Increasing efficiency and enhancing value in health care: ways to achieve savings in operating costs per year. In: IHI innovation series white paper. Institute for Healthcare Improvement, Cambridge, MA

    Google Scholar 

  • Mitton C, Seixas BV, Peacock S, Burgess M, Bryan S (2019) Health technology assessment as part of a broader process for priority setting and resource allocation. Appl Health Econ Health Policy 17(5):573–576. https://doi.org/10.1007/s40258-019-00488-1

    Article  Google Scholar 

  • Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A (2019) What is pharmacoepidemiology? definition, methods, interest and clinical applications. Therapie 74(2):169–174. https://doi.org/10.1016/j.therap.2018.08.001

    Article  Google Scholar 

  • Nishtala P, Bala S (2019) Sources of data used in pharmacoepidemiology and pharmacovigilance. In: Encyclopedia of pharmacy practice and clinical pharmacy, 1st edn. Elsevier, Amsterdam, The Netherlands, pp 391–399

    Google Scholar 

  • OECD (2019) Using routinely collected data to inform pharmaceutical policies. Analytical Report for OECD and European Countries, available from: https://www.oecd.org/health/health-systems/Using-Routinely-Collected-Data-to-Inform-Pharmaceutical-Policies-Analytical-Report-2019.pdf. Accessed on May 10, 2021

  • OECD (2020) European Union, health at a glance: Europe 2020: state of health in the EU cycle. OECD Publishing, Paris

    Google Scholar 

  • O'Rourke B, Oortwijn W, Schuller T, International Joint Task Group (2020) The new definition of health technology assessment: a milestone in international collaboration. Int J Technol Assess Health Care 36(3):187–190. https://doi.org/10.1017/S0266462320000215

  • Page RL 2nd, Linnebur SA, Bryant LL, Ruscin JM (2010) Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging 7(5):75–87. https://doi.org/10.2147/cia.s9564

    Article  Google Scholar 

  • Paterson JM, Laupacis A, Bassett K, Anderson GM (2006) BC-Ontario pharmacosurveillance for decision-making collaborative. using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative. Health Aff (Millwood) 25(5):1436–1443. https://doi.org/10.1377/hlthaff.25.5.1436

  • Piatkiewicz TJ, Traulsen JM, Holm-Larsen T (2018) Risk-sharing agreements in the EU: a systematic review of major trends. Pharmacoecon Open 2(2):109–123. https://doi.org/10.1007/s41669-017-0044-1

    Article  Google Scholar 

  • Pulini AA, Caetano GM, Clautiaux H, Vergeron L, Pitts PJ, Katz G (2021) Impact of real-world data on market authorization, reimbursement decision & price negotiation. Ther Innov Regul Sci. 55(1):228–238. https://doi.org/10.1007/s43441-020-00208-1

    Article  Google Scholar 

  • Qi W, Abu-Hanna A, van Esch TEM, de Beurs D, Liu Y, Flinterman LE, Schut MC (2021) Explaining heterogeneity of individual treatment causal effects by subgroup discovery: an observational case study in antibiotics treatment of acute rhino-sinusitis. Artif Intell Med 116:102080. https://doi.org/10.1016/j.artmed.2021.102080

    Article  Google Scholar 

  • Robinson S, Williams I, Dickinson H, Freeman T, Rumbold B (2012) Priority-setting and rationing in healthcare: evidence from the English experience. Soc Sci Med 75(12):2386–2393. https://doi.org/10.1016/j.socscimed.2012.09.014

    Article  Google Scholar 

  • Sacristán JA, Soto J (1994) Drug utilisation studies as tools in health economics. Pharmacoeconomics 5(4):299–312. https://doi.org/10.2165/00019053-199405040-00005

    Article  Google Scholar 

  • Salas-Vega S, Iliopoulos O, Mossialos E (2017) Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol 3(3):382–390. https://doi.org/10.1001/jamaoncol.2016.4166

    Article  Google Scholar 

  • Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337. https://doi.org/10.1016/j.jclinepi.2004.10.012

    Article  Google Scholar 

  • Sinnott SJ, Bennett K, Cahir C (2017) Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data. Eur J Clin Pharmacol 73(11):1449–1455. https://doi.org/10.1007/s00228-017-2310-7. Epub Aug 17 2017. Erratum in: Eur J Clin Pharmacol. 2017 73(11):1457

  • Sorenson C (2010) Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison. Issue Brief (commonw Fund) 91:1–14

    Google Scholar 

  • Souliotis K, Giannouchos TV, Golna C et al (2022) Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic. Qual Life Res 31:193–204. https://doi.org/10.1007/s11136-021-02917-y

    Article  Google Scholar 

  • Specchia ML, Favale M, Di Nardo F et al (2015) HTA working group of the Italian society of hygiene, preventive medicine and public health (SItI). How to choose health technologies to be assessed by HTA? a review of criteria for priority setting. Epidemiol Prev 39(4 Suppl 1):39–44

    Google Scholar 

  • Spillane S, Usher C, Bennett K, Adams R, Barry M (2015) Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors. J Pharm Pol Pract 8(Suppl 1):O10

    Google Scholar 

  • Stavrou A, Challoumas D, Dimitrakakis G (2014) Archibald Cochrane (1909–1988): the father of evidence-based medicine. Interact Cardiovasc Thorac Surg 18(1):121–124. https://doi.org/10.1093/icvts/ivt451

    Article  Google Scholar 

  • Storm BL (2000) Pharmacoepidimiology, 3rd edn. Wiley

    Google Scholar 

  • Takahashi Y, Nishida Y, Asai S (2012) Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 68(2):123–129. https://doi.org/10.1007/s00228-011-1088-2

    Article  Google Scholar 

  • Thokala P, Devlin N, Marsh K et al (2016) Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Heal 19(1):1–13

    Article  Google Scholar 

  • Tromp N, Baltussen R (2012) Mapping of multiple criteria for priority setting of health interventions: an aid for decision makers. BMC Health Serv Res 13(12):454. https://doi.org/10.1186/1472-6963-12-454

    Article  Google Scholar 

  • U.S. Food & Drug Administration (2018) Framework for FDA’s real-world evidence program, December, available from: https://www.fda.gov/media/120060/download. Accessed on May 4, 2021

  • van Luijn JC, Gribnau FW, Leufkens HG (2007) Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 63(2):159–162. https://doi.org/10.1111/j.1365-2125.2006.02812.x

    Article  Google Scholar 

  • Vreman RA, Bouvy JC, Bloem LT, Hövels AM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG (2019) Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally Approved Drugs. Clin Pharmacol Ther 105(3):684–691. https://doi.org/10.1002/cpt.1251

    Article  Google Scholar 

  • Vreman RA, Naci H, Goettsch WG, Mantel-Teeuwisse AK, Schneeweiss SG, Leufkens HGM, Kesselheim AS (2020) Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clin Pharmacol Ther 108(2):350–357. https://doi.org/10.1002/cpt.1835

    Article  Google Scholar 

  • Wettermark B (2013) The intriguing future of pharmacoepidemiology. Eur J Clin Pharmacol 69(Suppl 1):43–51. https://doi.org/10.1007/s00228-013-1496-6. Epub 2013 May 3

    Article  Google Scholar 

  • Wettermark B, Elseviers M, Almarsdóttir AB et al (2016) Introduction to drug utilization research. In: Methods and Application. Wiley

    Google Scholar 

  • World Health Organization, Health technology assessment, retrieved from: Health technology assessment-Global (who.int). Accessed on Apr 23, 2021

    Google Scholar 

  • Yuasa A, Yonemoto N, Demiya S, Foellscher C, Ikeda S (2021) Investigation of factors considered by health technology assessment agencies in eight countries. Pharmacoecon Open 5(1):57–69. https://doi.org/10.1007/s41669-020-00235-6

    Article  Google Scholar 

  • Zisis K, Naoum P, Athanasakis K (2020) Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries. Int J Technol Assess Health Care 10(37):e2. https://doi.org/10.1017/S0266462320002081

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece

    Konstantinos Zisis & Kostas Athanasakis

  2. Institute for Health Economics, Athens, Greece

    Konstantinos Zisis

  3. Department of Social and Education Policy, University of Peloponnese, Corinth, Greece

    Kyriakos Souliotis

  4. Health Policy Institute, Athens, Greece

    Kyriakos Souliotis

Authors
  1. Konstantinos Zisis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kostas Athanasakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyriakos Souliotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos Zisis .

Editor information

Editors and Affiliations

  1. Department of Quantitative Methods, School of Business, Istanbul University, Istanbul, Türkiye

    Eyüp Çetin

  2. Department of Business Administration, Faculty of Business Administration and Economics, Trakya University, Edirne, Türkiye

    Hilal Özen

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zisis, K., Athanasakis, K., Souliotis, K. (2023). Using Pharmacoepidemiologic Studies to Inform Drug Policy and Spending: A Health Economics Perspective. In: Çetin, E., Özen, H. (eds) Healthcare Policy, Innovation and Digitalization. Accounting, Finance, Sustainability, Governance & Fraud: Theory and Application. Springer, Singapore. https://doi.org/10.1007/978-981-99-5964-8_3

Download citation

Publish with us

Policies and ethics

Search

Navigation